Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.
first published: Nov 20, 2012 12:20 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty recovers 100 pts from day's lows in a choppy session; smallcaps shine | Closing Bell
Live: Can Nifty reclaim 26,000 after RS 7.5 lakh crore selloff? | IndiGo in focus | Opening Bell
Live: Sensex, Nifty fall 1% amidst broad-based selloff | Closing Bell
Live: Can Nifty reclaim record levels as investors await FOMC decision this week? | Opening Bell
